
Cipla Limited has informed the Exchange about press release dated 14-Jun-2022 titled Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa
Filed with NSE · · 4 pages · English
This new formulation has been approved by the South African Health Products Regulatory Authority and is designed to improve adherence among infants and young children. The treatment is a significant advancement over previous formulations, as it does not require refrigeration and is easier to administer. Cipla aims to enhance access to life-saving solutions for children suffering from HIV with this innovative product.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Cipla Limited has informed the Exchange about press release dated 14-Jun-2022 titled Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa
Follow Cipla into a list and get an email when it puts out news.
Follow Cipla